Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 987-995

  Banerjee, Amrita ^a   Sanyal, Sulagna ^a   Kulkarni, Kirti K ^b   Jana, Kuladip ^c   Roy, Siddhartha ^d   Das, Chandrima ^a   Dasgupta, Dipak ^a  

^a SAHA INSTITUTE OF NUCLEAR PHYSICS   (India)

^b Bionivid Technology Private Limited   (India)

^c BOSE INSTITUTE   (India)

^d INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Core histones; Dual binding mode; Epigenetic modulator; H3K18 acetylation; Mithramycin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; HISTONE ACETYLTRANSFERASE; HISTONE H3; LYSINE; MITHRAMYCIN;

ARTICLE; CHROMATIN; CIRCULAR DICHROISM; DISSOCIATION CONSTANT; DNA BINDING MOTIF; DOWN REGULATION; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; EWING SARCOMA CELL LINE; HELA CELL LINE; HISTONE ACETYLATION; HISTONE MODIFICATION; ISOTHERMAL TITRATION CALORIMETRY; OSTEOSARCOMA; TRANSCRIPTION REGULATION;

EID: 84912005992     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2014.10.007     Document Type: Article

References (53)

1. Lombo F., Menendez N., Salas J.A., Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl. Microbiol. Biotechnol. 2006, 73:1-14.
2. Torrance C.J., Agrawal V., Vogelstein B., Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 2001, 19:940-945.
3. Sleiman S.F., Langley B.C., Basso M., Berlin J., Xia L., Payappilly J.B., Kharel M.K., Guo H., Marsh J.L., Thompson L.M., Mahishi L., Ahuja P., Maclellan W.R., Geschwind D.H., Coppola G., Rohr J., Ratan R.R. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J. Neurosci. 2011, 31:6858-6870.
4. Sleiman S.F., Berlin J., Basso M., Karuppagounder S., Rohr J.R., Ratan R.R. Histone deacetylase inhibitors and mithramycin A impact a similar neuroprotective pathway at a crossroad between cancer and neurodegeneration. Pharmaceuticals 2011, 4:1183-1195.
5. Chatterjee S., Zaman K., Ryu H., Conforto A., Ratan R.R. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann. Neurol. 2001, 49:345-354.
6. Ferrante R.J., Ryu H., Kubilus J.K., D'mello S., Sugars K.L., Lee J., Lu P., Smith K., Browne S., Beal M.F., Kristal B.S., Stavrovskaya I.G., Hewett S., Rubinsztein D.C., Langley B., Ratan R.R. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 2004, 24:10335-10342.
7. Qiu Z., Norflus F., Singh B., Swindell M.K., Buzescu R., Bejarano M., Chopra R., Zucker B., Benn C.L., Dirocco D.P. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 2006, 281:16672-16680.
8. Ryu H., Lee J., Hagerty S.W., Soh B.Y., Mcalpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. 2006, 103:19176-19181.
9. Voisine C., Varma H., Walker N., Bates E.A., Stockwell B.R., Hart A.C. Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One 2007, 2:e504.
10. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., Goldstein D.R., Matson S., Goodrich S., Markey A.L., Cormier K., Hagerty S.W., Smith K., Ryu H., Ferrante R.J. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
11. Gaspar N., Di Giannatale A., Geoerger B., Redini F., Corradini N., Enz-Werle N., Tirode F., Marec-Berard P., Gentet J.C., Laurence V., Piperno-Neumann S., Oberlin O., Brugieres L. Bone sarcomas: from biology to targeted therapies. Sarcoma 2012, 2012:301975.
12. Sampi K., Hozumi M., Kumai R., Honma Y., Sakurai M. Differentiation of blasts from patients in myeloid crisis of chronic myelogenous leukemia by in-vivo and in-vitro plicamycin treatment. Leuk. Res. 1987, 11:1089-1092.
13. Ueki K., Tsuchida A., Murakami H., Karasawa M., Kobayashi N., Omine M., Naruse T. Myeloid crisis of chronic myelogenous leukemia showing dramatic response to mithramycin and hydroxyurea combination. Rinsho Ketsueki 1989, 30:1840-1842.
14. Brown J.H., Kennedy B.J. Mithramycin in the treatment of disseminated testicular neoplasms. N. Engl. J. Med. 1965, 272:111-118.
15. Kennedy B.J., Griffen W.O., Lober P. Specific effect of mithramycin on embryonal carcinoma of the testis. Cancer 1965, 18:1631-1636.
16. Kennedy B.J., Torkelson J.L. Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med. Pediatr. Oncol. 1995, 24:327-328.
17. Jia Z., Gao Y., Wang L., Li Q., Zhang J., Le X., Wei D., Yao J.C., Chang D.Z., Huang S., Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010, 70:1111-1119.
18. Yuan P., Wang L., Wei D., Zhang J., Jia Z., Li Q., Le X., Wang H., Yao J., Xie K. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007, 110:2682-2690.
19. Malek A., Nunez L.E., Magistri M., Brambilla L., Jovic S., Carbone G.M., Moris F., Catapano C.V. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 2012, 7:e35130.
20. ++ complex. Biochem. Biophys. Res. Commun. 1990, 173:689-696.
21. Mir M.A., Majee S., Das S., Dasgupta D. Association of chromatin with anticancer antibiotics, mithramycin and chromomycin A3. Bioorg. Med. Chem. 2003, 11:2791-2801.
22. 2+ coordination. Biochimie 1995, 77:729-738.
23. Chakraborty H., Devi P.G., Sarkar M., Dasgupta D. Multiple functions of generic drugs: future perspectives of aureolic acid group of anti-cancer antibiotics and non-steroidal anti-inflammatory drugs. Mini Rev. Med. Chem. 2008, 8:331-349.
24. 2+ complexes of chromomycin A3 and mithramycin with poly (dG-dC)·poly (dC-dG) and poly (dG)·poly (dC). Biochemistry 1997, 36:2291-2299.
25. 2+ complexes with DNA. Biochemistry 1995, 34:1376-1385.
26. Snyder R.C., Ray R., Blume S., Miller D.M. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry 1991, 30:4290-4297.
27. Hardenbol P., Van Dyke M.W. In vitro inhibition of c-myc transcription by mithramycin. Biochem. Biophys. Res. Commun. 1992, 185:553-558.
28. Campbell V.W., Davin D., Thomas S., Jones D., Roesel J., Tran-Patterson R., Mayfield C.A., Rodu B., Miller D.M., Hiramoto R.A. The G-C specific DNA binding drug, mithramycin, selectively inhibits transcription of the C-MYC and C-HA-RAS genes in regenerating liver. Am. J. Med. Sci. 1994, 307:167-172.
29. Vigneswaran N., Thayaparan J., Knops J., Trent J., Potaman V., Miller D.M., Zacharias W. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin. Biol. Chem. 2001, 382:329-342.
30. Selvi B.R., Pradhan S.K., Shandilya J., Das C., Sailaja B.S., Shankar G.N., Gadad S.S., Reddy A., Dasgupta D., Kundu T.K. Sanguinarine interacts with chromatin, modulates epigenetic modifications, and transcription in the context of chromatin. Chem. Biol. 2009, 16:203-216.
31. Banerjee A., Majumder P., Sanyal S., Singh J., Jana K., Das C., Dasgupta D. The DNA intercalators ethidium bromide and propidium iodide also bind to core histones. FEBS Open Bio 2014, 4:251-259.
32. Ghosh S., Majumder P., Pradhan S.K., Dasgupta D. Mechanism of interaction of small transcription inhibitors with DNA in the context of chromatin and telomere. Biochim. Biophys. Acta 2010, 1799:795-809.
33. Dasgupta D., Majumder P., Banerjee A. A revisit of the mode of interaction of small transcription inhibitor with genomic DNA. J. Biosci. 2012, 37:475-481.
34. Daujat S., Bauer U.M., Shah V., Turner B., Berger S., Kouzarides T. Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol. 2002, 12:2090-2097.
35. Lahiri S., Devi P.G., Majumder P., Das S., Dasgupta D. Self-association of the anionic form of the DNA-binding anticancer drug mithramycin. J. Phys. Chem. B 2008, 112:3251-3258.
36. Blobel G., Potter V.R. Nuclei from rat liver: isolation method that combines purity with high yield. Science 1966, 154:1662-1665.
37. Majumder P., Dasgupta D. Effect of DNA groove binder distamycin A upon chromatin structure. PLoS One 2011, 6:e26486.
38. Peterson C.L., Hansen J.C. Chicken erythrocyte histone octamer preparation. CSH Protoc. 2008, 2008. (pdb prot5112).
39. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., Kundu T.K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279:33716-33726.
40. Sinha M., Ghose J., Bhattarcharyya N.P. Micro RNA -214, -150, -146a and-125b target Huntingtin gene. RNA Biol. 2011, 8:1005-1021.
41. WAF1 expression. Mol. Cell. Biol. 2006, 26:2947-2954.
42. Mir M.A., Dasgupta D. Interaction of antitumor drug, mithramycin, with chromatin. Biochem. Biophys. Res. Commun. 2001, 280:68-74.
43. Chakrabarti S., Roy P., Dasgupta D. Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties. Biochem. Pharmacol. 1998, 56:1471-1479.
44. Wolffe, A. (1998) Chromatin: structure and function. Access Online via Elsevier.
45. Feng H.P., Scherl D.S., Widom J. Lifetime of the histone octamer studied by continuous-flow quasielastic light scattering: test of a model for nucleosome transcription. Biochemistry 1993, 32:7824-7831.
46. Khan S.N., Yennamalli R., Subbarao N., Khan A.U. Mitoxantrone induced impediment of histone acetylation and structural flexibility of the protein. Cell Biochem. Biophys. 2011, 60:209-218.
47. Jin Q., Yu L.R., Wang L., Zhang Z., Kasper L.H., Lee J.E., Wang C., Brindle P.K., Dent S.Y., Ge K. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 2011, 30:249-262.
48. Grohar P.J., Woldemichael G.M., Griffin L.B., Mendoza A., Chen Q.R., Yeung C., Currier D.G., Davis S., Khanna C., Khan J., Mcmahon J.B., Helman L.J. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J. Natl Cancer Inst. 2011, 103:962-978.
49. Devi P.G., Pal S., Banerjee R., Dasgupta D. Association of antitumor antibiotics, mithramycin and chromomycin, with Zn(II). J. Inorg. Biochem. 2007, 101:127-137.
50. Majumder P., Banerjee A., Shandilya J., Senapati P., Chatterjee S., Kundu T.K., Dasgupta D. Minor groove binder distamycin remodels chromatin but inhibits transcription. PLoS One 2013, 8:e57693.
51. Rabbani A., Finn R.M., Thambirajah A.A., Ausio J. Binding of antitumor antibiotic daunomycin to histones in chromatin and in solution. Biochemistry 2004, 43:16497-16504.
52. Hajihassan Z., Rabbani-Chadegani A. Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution. Int. J. Biol. Macromol. 2011, 48:87-92.
53. 2 duplex: calorimetric and spectroscopic studies. J. Mol. Biol. 1997, 271:244-257.